The Priority Review

Tag

maridebart cafraglutide

1 story

  1. Clinical trials

    Amgen registers Phase 3 trial of maridebart cafraglutide versus semaglutide in type 2 diabetes

    The study, NCT07866066, plans to enroll 1300 participants and start on November 2, 2026. It plans to compare maridebart cafraglutide once monthly versus semaglutide once weekly as add-on therapy to metformin with or without a sodium-glucose cotransporter-2 inhibitor.